Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/105299
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang, L. | - |
dc.contributor.author | Liu, X. | - |
dc.contributor.author | Pascoe, E. | - |
dc.contributor.author | Badve, S. | - |
dc.contributor.author | Boudville, N. | - |
dc.contributor.author | Clayton, P. | - |
dc.contributor.author | De Zoysa, J. | - |
dc.contributor.author | Hawley, C. | - |
dc.contributor.author | Kanellis, J. | - |
dc.contributor.author | McDonald, S. | - |
dc.contributor.author | Peh, C. | - |
dc.contributor.author | Polkinghorne, K. | - |
dc.contributor.author | Johnson, D. | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | Nephrology, 2016; 21(5):387-396 | - |
dc.identifier.issn | 1320-5358 | - |
dc.identifier.issn | 1440-1797 | - |
dc.identifier.uri | http://hdl.handle.net/2440/105299 | - |
dc.description.abstract | Background: Clinical outcomes of patients with end-stage kidney disease (ESKD) receiving renal replacement therapy (RRT) secondary to IgA nephropathy (IgAN) have not been well described. Aim: To investigate the characteristics, treatments and outcomes of ESKD because of kidney-limited IgAN and Henoch-Schönlein purpura nephritis (HSPN) in the Australian and New Zealand RRT populations. Methods: All ESKD patients who commenced RRT in Australia and New Zealand between 1971 and 2012 were included. Dialysis and transplant outcomes were evaluated in both a contemporary cohort (1998-2012) and the entire cohort (1971-2012). Results: Of 63 297 ESKD patients, 3721 had kidney-limited IgAN, and 131 had HSPN. For the contemporary cohort of IgAN patients on dialysis (n = 2194), 10-year patient survival was 65%. Of 1368 contemporary IgAN patients who received their first renal allograft, 10-year patient, overall renal allograft and death-censored renal allograft survival were 93%, 82% and 88%, respectively. Using multivariable Cox regression analysis, patients with IgAN had favourable dialysis patient survival (adjusted hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.57-0.69), overall renal allograft survival (HR 0.67, 95% CI 0.57-0.79) and renal transplant patient survival (HR 0.58, 95% CI 0.45-0.74) compared with ESKD controls. Similar results were found in the entire cohort and when using competing-risks models. Compared with kidney-limited IgAN patients, those with HSPN had worse dialysis patient survival (HR 1.94, 95% CI 1.02-3.69), overall renal allograft survival (HR 3.40, 95% CI 1.00-11.55) and renal transplant patient survival (HR 3.50, 95% CI 1.03-11.92). Conclusion: IgAN ESKD was associated with better dialysis and renal transplant outcomes compared with other forms of ESKD. The survival outcomes of ESKD patients with HSPN were worse than kidney-limited IgAN. | - |
dc.description.statementofresponsibility | Lei Zhang, Xusheng Liu, Elaine M Pascoe, Sunil V Badve, Neil C Boudville, Philip A Clayton, Janak De Zoysa, Carmel M Hawley, John Kanellis, Stephen P McDonald, Chen Au Peh, Kevan R Polkinghorne and David W Johnson | - |
dc.language.iso | en | - |
dc.publisher | Wiley | - |
dc.rights | © 2015 Asian Pacific Society of Nephrology 387 | - |
dc.source.uri | http://dx.doi.org/10.1111/nep.12629 | - |
dc.subject | Dialysis; end-stage kidney disease; Henoch-Schönlein purpura; IgA nephropathy; outcomes; renal transplantation | - |
dc.title | Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: a multi-centre registry study | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/nep.12629 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Clayton, P. [0000-0001-9190-6753] | - |
dc.identifier.orcid | McDonald, S. [0000-0001-6103-1386] | - |
dc.identifier.orcid | Peh, C. [0000-0002-9712-0396] | - |
Appears in Collections: | Aurora harvest 3 Public Health publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.